Constipation on Wegovy (semaglutide 2.4 mg): Incidence, Severity, and Realistic Expectations
How common is constipation on Wegovy? Trial-level incidence data, severity breakdown, risk factors, typical timeline, and when to call your prescriber.
WEGOVY Constipation: Side Effects
15 clinically reviewed articles, written and peer-reviewed by the HealthRX.com Medical Team.
15articles
4topic areas covered
May 25, 2026latest review
WEGOVY Constipation: Side Effects library
Showing 15 of 15 clinical reviews.
Constipation on Wegovy (semaglutide 2.4 mg): Week-by-Week Timeline of What to Expect
A phase-by-phase breakdown of when constipation starts, peaks, and typically resolves during Wegovy dose escalation, backed by STEP trial data and GI motility research.
Diet and Lifestyle for Constipation on Wegovy (semaglutide 2.4 mg): What Actually Works
Specific dietary changes, hydration targets, meal-timing strategies, and evidence-backed supplements that reduce constipation caused by Wegovy (semaglutide 2.4 mg).
Foods That Help Wegovy Constipation: Diet Protocols Backed by Clinical Evidence
Evidence-based dietary strategies to relieve constipation caused by Wegovy (semaglutide 2.4 mg), including fiber protocols, hydration targets, and foods to prioritize or avoid.
Managing Constipation on Wegovy (semaglutide 2.4 mg): The HealthRX.com Step-by-Step Protocol
A clinically specific, step-by-step protocol for assessing and treating constipation caused by Wegovy (semaglutide 2.4 mg), including first-line interventions, escalation criteria, and discontinuation triggers.
Medications to Manage Constipation on Wegovy (semaglutide 2.4 mg): First-Line and Beyond
OTC and prescription options for treating constipation caused by Wegovy (semaglutide 2.4 mg), including first-line osmotic laxatives, second-line prokinetics, drug interactions to avoid, and when to escalate care.
Using Dose Titration to Resolve Constipation on Wegovy (semaglutide 2.4 mg)
Clinical protocols for adjusting Wegovy dose titration to manage constipation, including slower escalation, dose pausing, step-downs, and microdosing approaches.
Wegovy (Semaglutide 2.4 mg) Constipation: Alternatives Without This Side Effect
Wegovy causes constipation in up to 24% of users. Learn why semaglutide slows gut transit, how to manage it, and which GLP-1 alternatives carry a lower constipation burden.
Wegovy (Semaglutide 2.4 mg) Constipation: Severity Grading Rubric and Management Guide
A clinical guide to grading constipation severity on Wegovy (semaglutide 2.4 mg), with evidence-based management strategies, mechanistic explanations, and when to contact your prescriber.
Wegovy (Semaglutide 2.4 mg) Constipation: Supplements with the Best Evidence
Wegovy slows gut transit and causes constipation in roughly 24% of users. This evidence-based guide covers why it happens, how long it lasts, and which supplements have the strongest clinical support for relief.
Wegovy (Semaglutide 2.4 mg) Constipation: When to Call the Doctor
Learn when constipation from Wegovy (semaglutide 2.4 mg) requires medical attention, why GLP-1 agonists slow gut transit, and how to manage this common side effect safely.
Wegovy Constipation That Won't Go Away: Causes, Red Flags, and Evidence-Based Fixes
Persistent constipation on Wegovy (semaglutide 2.4 mg) affects up to 24% of patients. Learn why it happens, when to worry, and clinician-backed strategies to restore normal bowel function.
When Constipation on Wegovy (semaglutide 2.4 mg) Becomes a Reason to Stop
Clinical criteria for discontinuing Wegovy due to constipation, including severity thresholds, lab red flags, quality-of-life impact, and alternative GLP-1 options.
Why Wegovy (Semaglutide 2.4 mg) Causes Constipation: The Mechanism Explained
Clinical explanation of how semaglutide slows gut transit time across the entire GI tract, causing constipation in Wegovy patients, with actionable management steps.
Why Wegovy Causes Constipation: The GI Biology Behind Slowed Gut Transit
A clinical deep-dive into how semaglutide 2.4 mg slows gut motility and causes constipation, including the GLP-1 receptor pathways involved, trial data from STEP-1 through STEP-5, and evidence-based management strategies.